Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
NYSE:NVO
NVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$77.82 - $148.15
Previous CloseN/A
Volume3.65M
Average Volume (3M)9.55M
Market Cap
$364.07B
Enterprise Value$393.88B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)25.0
Beta0.76
Next Earnings
May 07, 2025EPS Estimate
0.9Next Dividend Ex-Date
Mar 31, 2025Dividend Yield1.25%
Share Statistics
EPS (TTM)3.29
Shares Outstanding3,390,128,000
10 Day Avg. Volume8,973,721
30 Day Avg. Volume9,549,438
Standard Deviation0.07
R-Squared0.11
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.39
Price to Cash Flow (P/CF)69.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$100.10Price Target Upside20.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
AcquisitionNovo Holdings is set to win EU antitrust approval for their proposed acquisition of Catalent, which is positive for Novo shares.
Growth PotentialEPS clipped slightly but still looking for +13% CAGR through 2030 and improved supply supports topline.
Market PositionNVO is well positioned in the growing diabetes and obesity market.
Bears Say
Debt FinancingThe acquisition is mainly debt-financed, with interest payments negatively impacting net financial items.
Financial PerformanceNovo guides to low single-digit negative operating profit growth impact in 2024 and mid-single digit impact in 2025, mostly associated with depreciation and amortization.
Investor ExpectationsCagriSema results likely underperform investor expectations reporting efficacy-estimand weight loss of 22.7% and treatment-estimand weight loss of 20.4%.
---
Ownership Overview
―
Insiders
1.56% Mutual Funds
5.17% Other Institutional Investors
93.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $77.82 and its highest was $148.15 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $364.07B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is May 07, 2025 which is in 76 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Feb 05, 2025. The company reported $0.886 earnings per share for the quarter, beating the consensus estimate of $0.831 by $0.055.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.787 which represents an annual dividend yield of 1.25%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.9.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.886 in its last earnings report, beating expectations of $0.831. Following the earnings report the stock price went up 3.764%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in NVO
---
Novo Nordisk Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$100.10 (20.02% Upside)
$100.10 (20.02% Upside)
Blogger Sentiment
Bullish
NVO Sentiment 86%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 552.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.22%
12-Months-Change
Fundamentals
Return on Equity
82.03%
Trailing 12-Months
Asset Growth
38.79%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S is a Denmark-based healthcare company, which manufactures and markets pharmaceutical products globally. The company operates through two segments, including Diabetes & Obesity Care, and Biopharmaceuticals. The company was founded in 1925.
---
NVO Company Deck
---
NVO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong financial performance and strategic growth in key areas such as GLP-1 treatments and obesity care, supported by significant R&D achievements. However, challenges remain with increased carbon emissions, supply constraints, and issues in the rare diseases segment. Despite these challenges, the positive developments in sales, profit, and R&D outcomes suggest more highlights than lowlights.Read More>---
NVO Stock 12 Month Forecast
Average Price Target
$100.10
▲(20.02% Upside)
Technical Analysis
Best Analysts Covering NVO
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-7.66%
reiterated a buy rating 16 days ago
Copying Michael Nedelcovych's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -7.66% per trade.
---